Sulzer Medica bid to convert final opt-outs in US implants case
This article was originally published in Clinica
Executive Summary
Sulzer Medica last week found that it was not yet out of the woods in its efforts to settle US claims for compensation following problems with its hip and knee implants, when 120 plaintiffs refused to opt in for a share of the $1 billion compensation on offer from the Zurich, Switzerland company. 99.6% of plaintiffs opted for the package by the May 15 deadline, but the laggard 0.4% could present sizeable problems, and perhaps still force Sulzer's US orthopaedic subsidiary into bankruptcy.